NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
H1 FY27 PAT Drops 48.2% YoY to ₹6.09 Cr; Revenue Down 18% to ₹179.49 Cr
Mangalam Alloys reported its half-yearly results for the period ended September 30, 2026, showing revenue from operations of ₹179.49 Cr, an 18% decline compared to ₹218.78 Cr in the half-year ended September 30, 2025. Net profit fell 48.2% YoY to ₹6.09 Cr from ₹11.76 Cr, with basic EPS decreasing to ₹2.47 compared to ₹4.76 last year. However, sequentially, net profit rebounded sharply from ₹2.91 Cr reported in the half-year ended March 31, 2026. Total borrowings expanded to ₹306.41 Cr, while no deviations were reported in the utilization of IPO proceeds.
உச்சம் நம்பிக்கை
என்ன மாறியதுMangalam Alloys approved and reported unaudited financial results for the half-year ended September 30, 2026, alongside an IPO funds utilization statement with zero deviations.
ஏன் இது முக்கியம்The business experienced top-line compression and lower year-on-year profitability amid higher finance costs, highlighting continued pressure on its steel product lines.
Revenue from operations (H1 FY27): ₹179.49 கோடிNet Profit (H1 FY27): ₹6.09 கோடிTotal Borrowings as of Sept 30, 2026: ₹306.41 கோடிFinance Costs (H1 FY27): ₹17.03 கோடி
📅 குறுகிய காலம்Weak year-on-year earnings growth and higher interest obligations may dampen near-term stock sentiment despite sequential PAT improvement over H2 FY26.
📈 நீண்ட காலம்Structural margins depend on passing through raw material price volatility and successfully scaling higher-value products to service high balance-sheet debt.
⚠ அபாய எச்சரிக்கைகள்
High debt burden with ₹306.41 Cr in total borrowings vs ₹163.94 Cr net worth
Elevated finance costs (₹17.03 Cr for the half-year) depressing net margins
Substantial top-line contraction YoY
👀 கவனிக்க வேண்டியவை
Track subsequent revenue traction and operating margins in H2 FY27, along with the company's ability to reduce finance costs and manage high leverage.
Q2 FY27 Net Profit at ₹35 Cr Down 7% YoY; Record Order Inflow of ₹1,198 Cr
GMM Pfaudler reported Q2 FY27 consolidated revenue of ₹1,065 crore, up 18% YoY and 15% QoQ. Operating EBITDA declined 9% YoY to ₹110 crore with margins shrinking to 10.3%, while consolidated PAT decreased 7% YoY to ₹35 crore. The company achieved its highest-ever quarterly order intake of ₹1,198 crore (up 36% YoY), lifting order backlog to a record ₹2,446 crore (~67% of TTM revenue). Additionally, net debt was reduced by approximately ₹116 crore during H1 FY27.
உச்சம் நம்பிக்கை
என்ன மாறியதுReported Q2 & H1 FY27 financial performance along with the formal appointment of Gregory Gelhaus as Group CEO and Ankit Nayyar as Group CFO.
ஏன் இது முக்கியம்Despite softer profitability and compressed margins (10.3% vs historical mid-teens), record order intake and debt reduction of ₹116 crore improve future execution visibility and balance sheet health.
Q2 FY27 Revenue: ₹1,065 கோடிQ2 FY27 PAT: ₹35 கோடிQ2 Order Intake: ₹1,198 கோடிOrder Backlog: ₹2,446 கோடிBacklog vs TTM Revenue: ~66.9%H1 Net Debt Repayment: ₹116 கோடி
📅 குறுகிய காலம்Margin contraction may cap immediate upside despite strong top-line and sequential PAT recovery (59% QoQ); commentary on pricing pressure in key chemical/pharma end-markets will be watched.
📈 நீண்ட காலம்Record backlog of ₹2,446 crore supports medium-term growth, while ongoing leadership realignment and cost-efficiency programs aim to structurally restore operational margins.
⚠ அபாய எச்சரிக்கைகள்
Margin compression with EBITDA margins at 10.3% vs historical levels
End-market concentration in chemical and pharmaceutical capex cycles
👀 கவனிக்க வேண்டியவை
Track the management commentary in the earnings call on November 5, 2026, specifically regarding margin recovery triggers and conversion timeline for the ₹2,446 crore order backlog.
Sundaram Finance H1FY27 PAT Rises 21% to ₹997 Cr; AUM Up 19% to ₹65,992 Cr
Sundaram Finance released its H1FY27 investor presentation reporting a 19% YoY growth in Assets Under Management (AUM) to ₹65,992 crore as of September 30, 2026. Standalone profit after tax for H1FY27 rose 21% YoY to ₹997 crore, driven by a 25% increase in disbursements to ₹19,302 crore and an 18% growth in net interest income to ₹1,888 crore. Asset quality improved, with Gross Stage 3 assets declining to 1.84% (down from 2.03% in Sep 2025) and Net Stage 3 at 0.91%. Return on Assets (ROA) improved to 2.86% compared to 2.72% in H1FY26, while core ROE stood at 17.5%.
உச்சம் நம்பிக்கை
என்ன மாறியதுSundaram Finance published its detailed H1FY27 financial metrics and investor presentation, showing accelerated AUM and disbursement growth.
ஏன் இது முக்கியம்Demonstrates strong operational momentum across auto lending, maintaining industry-leading asset quality and stable profitability with an ROA of 2.86%.
AUM (Sep 30, 2026): ₹65,992 கோடிDisbursements (H1FY27): ₹19,302 கோடிPAT (H1FY27): ₹997 கோடிGross Stage 3: 1.84%Net Interest Income (H1FY27): ₹1,888 கோடி
📅 குறுகிய காலம்Positive financial performance with solid disbursements and asset quality improvement should support market sentiment following recent quarterly results.
📈 நீண்ட காலம்Reinforces the company's multi-decade track record of consistent credit underwriting, low NPA levels, and steady 16-18% Core ROE generation.
⚠ அபாய எச்சரிக்கைகள்
Potential slowdown in underlying automotive sector volumes or rural cash flows
Net interest margin compression from an upward interest-rate cycle
Q2 PAT at ₹3.53 Cr Driven by Other Income; Operations Revenue Down 79% YoY to ₹1.15 Cr
Tainwala Chemicals and Plastics reported its Q2 FY27 (quarter ended September 30, 2026) results with net profit at ₹353.07 Lakhs (₹3.53 Cr), down 8.9% YoY from ₹387.63 Lakhs. Core revenue from operations dropped sharply by 78.7% YoY to ₹114.97 Lakhs from ₹540.90 Lakhs, as the company had zero purchases for resale compared to ₹442.49 Lakhs in Q2 FY26. Earnings were predominantly supported by other income of ₹410.88 Lakhs (mainly dividend and interest income). For H1 FY27, net profit stood at ₹355.58 Lakhs compared to ₹668.86 Lakhs in H1 FY26.
உச்சம் நம்பிக்கை
என்ன மாறியதுTainwala reported Q2 FY27 financial results showing a steep contraction in core operational revenue, offset by other income.
ஏன் இது முக்கியம்The company's core operations remain minimal (under ₹1.15 Cr per quarter), making its financial performance largely dependent on treasury and investment returns rather than plastic product sales.
Income from operations (Q2): 114.97 LakhsOther income (Q2): 410.88 LakhsProfit for the period (Q2): 353.07 LakhsBasic and Diluted EPS (Q2): 3.77Non-current Investments: 18,127.43 Lakhs
📅 குறுகிய காலம்Muted to negative market reaction is possible given the sharp shrinkage in top-line operational turnover, despite bottom-line resilience driven by non-operating income.
📈 நீண்ட காலம்Limited operational traction; the company operates effectively as an investment-holding entity with minor manufacturing revenue.
⚠ அபாய எச்சரிக்கைகள்
Earnings quality is low due to extreme reliance on non-operating other income
Core operations turnover dropped nearly 79% YoY
Negative operating cash flows of ₹58.36 Lakhs in H1
👀 கவனிக்க வேண்டியவை
Track whether core manufacturing and trading operational revenue recovers in subsequent quarters, as current earnings are almost entirely underpinned by investment income.
Mindteck Q2 FY27 Consolidated PAT at ₹7.48 Cr, Revenue Rises 3.8% YoY to ₹105.50 Cr
Mindteck (India) reported consolidated revenue of ₹105.50 crore for Q2 FY27, representing a 3.8% YoY increase and 1.4% sequential growth. Consolidated net profit came in at ₹7.48 crore, declining from ₹8.36 crore in Q1 FY27 and ₹7.56 crore in Q2 FY26. For H1 FY27, revenue reached ₹209.58 crore (up 3.3% YoY) while PAT stood at ₹15.84 crore compared to ₹16.31 crore last year (which included a ₹1.91 crore exceptional gain). The company maintained a robust cash and liquid investment buffer of ₹204.72 crore, up 21.2% YoY, which is significant relative to its ₹430 crore market cap.
உச்சம் நம்பிக்கை
என்ன மாறியதுMindteck released its Q2 and H1 FY27 operational and financial performance figures via press release.
ஏன் இது முக்கியம்Demonstrates resilient topline execution despite spending cuts by two key legacy accounts, supported by an exceptionally large cash cushion (~₹205 crore).
Consolidated Revenue Q2 FY27: Rs. 105.50 கோடிConsolidated Net Profit Q2 FY27: Rs. 7.48 கோடிH1 FY27 Revenue: Rs. 209.58 கோடிCash and Liquid Investments: Rs. 204.72 கோடிCash to Market Cap ratio: ~47.6%
📅 குறுகிய காலம்Performance is broadly stable with slight sequential margin compression; the stock may react neutrally given steady topline and lack of negative earnings surprises.
📈 நீண்ட காலம்The company is transitioning toward owning end-to-end engineering programs and AI solutions, though sustaining growth hinges on diversifying beyond concentrated storage and medical device accounts.
⚠ அபாய எச்சரிக்கைகள்
Client concentration risk noted by CEO as two long-standing clients scaled back spending
Standalone business showed de-growth YoY (revenue down to ₹31.91 crore vs ₹39.15 crore)
👀 கவனிக்க வேண்டியவை
Monitor client concentration risks following management commentary that two long-standing clients scaled back, and watch how quickly new managed engineering contracts ramp up revenue.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Sai Silks Releases Q2 FY27 Investor Presentation; H1 Operating Cash Flow at -₹29.74 Cr
Sai Silks (Kalamandir) has published its investor presentation detailing financial results for Q2 and H1 ended September 30, 2026. For H1 FY27, net profit before tax dropped to ₹75.86 Cr compared to ₹94.65 Cr in H1 FY26. Operating cash flow turned negative at -₹29.74 Cr against +₹180.37 Cr in the prior-year period, primarily driven by ₹143.67 Cr absorbed into inventory expansion. Total equity stood at ₹1,293.60 Cr with net cash and cash equivalents declining to ₹12.26 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுSai Silks shared its Q2/H1 FY27 investor presentation containing the balance sheet and cash flow statement for the period ended September 30, 2026.
ஏன் இது முக்கியம்Shows heavy working capital build-up (₹143.67 Cr in inventory) heading into the festive/wedding season, which strained operating cash flow down to -₹29.74 Cr.
H1 Net Profit Before Tax: ₹75.86 கோடிH1 Operating Cash Flow: -₹29.74 crH1 Inventory Outflow: ₹143.67 கோடிPPE & CWIP Capex: ₹27.28 கோடிCash & Cash Equivalents: ₹12.26 கோடி
📅 குறுகிய காலம்The filing gives deeper balance sheet details post-earnings; the market will look for strong festive sales conversions to monetize elevated inventory levels.
📈 நீண்ட காலம்Working capital discipline and sales per square foot productivity (moving toward the target of ₹50,000/sq ft) remain key to compounding earnings.
⚠ அபாய எச்சரிக்கைகள்
Negative operating cash flow due to elevated working capital lock-up in inventories
Drop in half-yearly pre-tax profits year-on-year
👀 கவனிக்க வேண்டியவை
Track festive season inventory liquidation in Q3 and monitor whether operating cash flows recover to positive levels alongside store productivity improvements.
Mindteck Q2 Standalone PAT Declines 29.7% YoY to ₹3.78 Cr; Revenue Down 18.5%
Mindteck (India) Limited reported its Q2 (quarter ended September 30, 2026) standalone financial results, posting revenue from operations of ₹31.91 crore, down 18.5% YoY from ₹39.15 crore in Q2 FY26. Standalone net profit for the quarter dropped 29.7% YoY to ₹3.78 crore compared to ₹5.38 crore in the prior year period. For the half-year (H1 FY27), standalone revenue stood at ₹65.84 crore versus ₹74.30 crore in H1 FY26, with PAT at ₹7.62 crore versus ₹10.04 crore. Additionally, the NRC granted 2,50,000 ESOP options to Key Managerial Personnel at an exercise price of ₹133.63 per share.
உச்சம் நம்பிக்கை
என்ன மாறியதுBoard approved Q2 and H1 unaudited financial results and granted 2.5 lakh ESOP options to KMP.
ஏன் இது முக்கியம்Demonstrates persistent top-line and bottom-line contraction on a standalone basis amid a tough demand environment for small-cap IT engineering services.
📅 குறுகிய காலம்Negative standalone performance may weigh on market sentiment following recent year-long stock underperformance.
📈 நீண்ட காலம்Limited, pending turnaround in core IT engineering demand and stabilization of top client accounts.
⚠ அபாய எச்சரிக்கைகள்
Revenue contraction YoY and QoQ
High client concentration in storage and medical device sectors
👀 கவனிக்க வேண்டியவை
Monitor client spending recovery in the US/Europe tech segments and tracking the release of the complete consolidated financial segmental breakdown.
Aarti Pharmalabs Q2 FY27 Call: Standalone Revenue Up 47% to ₹613 Cr; Targets ₹1,000 Cr CDMO Revenue
Aarti Pharmalabs reported its highest-ever standalone quarterly revenue of ₹613 crore in Q2 FY27, up 47% YoY from ₹417 crore, with EBITDA expanding 84% YoY to ₹136 crore and margins reaching 22.2%. Profit after tax rose 2.75x YoY to ₹66 crore on strong execution and steroid API capacity ramp-up. Xanthine derivatives contributed 50% of turnover, APIs 30%, and CDMO/CMO 13%, with CDMO targeting 40-50% growth this year. Management reiterated a medium-term target of ₹800-1,000 crore revenue from CDMO over the next 2-3 years, driven by 39 commercialized projects.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the formal transcript for the Q2 FY27 earnings conference call held on October 29, 2026.
ஏன் இது முக்கியம்Confirms strong operating leverage with EBITDA margins crossing 22% and provides concrete visibility on CDMO scaling towards a ₹1,000 crore pipeline over 2-3 years.
📅 குறுகிய காலம்Earnings commentary reflects positive momentum and raw material pass-through, though shipment constraints slightly weighed on Xanthine dispatches during Q2.
📈 நீண்ட காலம்Commissioning of Atali Phase 1 and dedicated Block 2 positions the company to transform from a Xanthine-dependent business into a diversified CDMO and API player.
⚠ அபாய எச்சரிக்கைகள்
Elevated raw material costs linked to geopolitical turmoil
Customer clinical trial dropouts impacting the under-development CDMO pipeline
👀 கவனிக்க வேண்டியவை
Track the full capitalization and commercialization of Atali Phase 1 in Q3 FY27 and the sequential ramp-up of expanded Xanthine capacity through Q4 FY27.
Manugraph Q2 FY27 Results: Rs 9.78 Cr Gain on Kolhapur Unit II Disposal Drives PBT to Rs 5.65 Cr
Manugraph India reported standalone results for the half year ended September 30, 2026, recording a Profit Before Tax of Rs 5.65 Cr (compared to Rs 0.42 Cr in H1 FY26). Performance was substantially aided by an exceptional gain of Rs 9.78 Cr (Rs 978.25 lakhs) from the disposal of immovable assets at its Kolhapur Unit II. Operating cash flows before working capital changes stood negative at Rs -9.55 Cr, reflecting continued operational challenges in its core business. Total borrowings were reduced to zero from Rs 6.00 Cr as of September 2025.
உச்சம் நம்பிக்கை
என்ன மாறியதுManugraph finalized the sale of land and buildings at Kolhapur Unit II, booking a Rs 9.78 Cr gain and eliminating its short-term debt.
ஏன் இது முக்கியம்While asset monetization provides immediate liquidity to pay down debt, core engineering operations continue to burn cash before working capital adjustments.
Gain on Kolhapur Unit II asset disposal: Rs 978.25 lakhsH1 PBT: Rs 564.50 lakhsOperating cash flow before WC changes: Rs -955.20 lakhsCurrent borrowings: Rs NilAsset disposal gain vs Market Cap: ~21.3%
📅 குறுகிய காலம்The headline profit growth will likely be recognized as driven by one-off asset monetization rather than operational turnaround.
📈 நீண்ட காலம்Asset downsizing reflects the structural decline in web offset printing presses; long-term sustainability hinges on the commercial scaling of flexo-packaging machines.
⚠ அபாய எச்சரிக்கைகள்
Core operations remain cash-negative (-Rs 9.55 Cr before WC adjustments in H1)
Earnings are skewed by non-recurring asset sales
Structural decline in newspaper printing machinery demand
👀 கவனிக்க வேண்டியவை
Track whether operational cash flows can turn positive without asset sales, and monitor the completion of documentation for the two-acre factory land sale at Unit I.
RCOM Classified as Wilful Defaulter by SBI Review Committee; Name Sent to CICs
Reliance Communications Limited (RCOM) has received a communication dated October 31, 2026, from State Bank of India (SBI) rejecting the company's representations against wilful defaulter classification. SBI's Review Committee for Wilful Defaulters has decided to forward the names of the company and its erstwhile promoter to Credit Information Companies (CICs). RCOM stated that since it is under Corporate Insolvency Resolution Process (CIRP) since June 28, 2019, it is protected under Section 14 and Section 32A of the IBC from pre-CIRP liabilities once a resolution plan is approved. The company is currently operating under insolvency with outstanding debt of Rs 39,934 Cr and a negative net worth of Rs 78,892 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுSBI's Review Committee rejected RCOM's representations and initiated the process to include the company and its erstwhile promoter in the list of Wilful Defaulters reported to CICs.
ஏன் இது முக்கியம்A wilful defaulter classification severely impedes future access to institutional credit and carries reputational and legal repercussions, although RCOM contends that IBC provisions provide statutory immunity post-resolution.
Total Debt: Rs 39934 கோடிNet Worth: Rs -78892 CrLetter Date: அக்டோபர் 31, 2026Letter Receipt Date: 03rd நவம்பர் 2026CIRP Commencement Date: ஜூன் 28, 2019
📅 குறுகிய காலம்Potential negative sentiment in the scrip; the Resolution Professional is seeking legal counsel regarding further courses of action.
📈 நீண்ட காலம்Equity value remains largely impaired given negative net worth and ongoing CIRP proceedings awaiting NCLT resolution.
⚠ அபாய எச்சரிக்கைகள்
Wilful defaulter classification reported to CICs
Massive debt burden of Rs 39,934 Cr and deeply negative net worth
Insolvency resolution plan pending NCLT approval since 2019
👀 கவனிக்க வேண்டியவை
Track the pending NCLT Mumbai approval of the CIRP resolution plan submitted by UV Stressed Assets Management, and monitor legal challenges against SBI's wilful defaulter classification.
BLB Limited Q2 FY27 Net Profit Drops 72% YoY to ₹2.48 Cr; Revenue Down 97% to ₹9.77 Cr
BLB Limited reported standalone Q2 FY27 revenue from operations of ₹9.77 Cr, falling sharply by 97.1% YoY from ₹338.70 Cr in Q2 FY26. Standalone net profit declined 72.3% YoY to ₹2.48 Cr compared to ₹8.95 Cr in the corresponding quarter last year. For H1 FY27, revenue stood at ₹102.99 Cr compared to ₹395.12 Cr in H1 FY26, with net profit declining 60.8% YoY to ₹8.02 Cr. Additionally, the board approved the appointment of M/s MAPSS and Company as Internal Auditors for FY 2026-27.
உச்சம் நம்பிக்கை
என்ன மாறியதுBLB Limited reported sharp declines in quarterly top-line and bottom-line for Q2 ended September 30, 2026, and appointed new internal auditors.
ஏன் இது முக்கியம்A 97% drop in quarterly operational revenue signals high revenue volatility inherent to proprietary securities trading and volume contraction.
Q2 FY27 Revenue from Operations: ₹9.77 கோடிQ2 FY27 Net Profit: ₹2.48 கோடிQ2 FY26 Revenue from Operations: ₹338.70 கோடிQ2 FY26 Net Profit: ₹8.95 கோடிH1 FY27 Net Profit: ₹8.02 கோடி
📅 குறுகிய காலம்The substantial contraction in trading revenues and profit may weigh negatively on short-term sentiment.
📈 நீண்ட காலம்Reflects the company's lack of pricing power and reliance on high-volume market trading spreads, which can induce severe earnings cyclicality.
⚠ அபாய எச்சரிக்கைகள்
Extreme top-line volatility inherent to the securities trading business model
Dependence on exchange trading volumes and market liquidity
👀 கவனிக்க வேண்டியவை
Track subsequent quarterly trading turnover and market spreads to see if trading volumes recover, alongside the operational contribution from newly formed subsidiaries.
Raymond Q2 FY27 Earnings Call: Income Up 21% YoY to ₹683 Cr, Aerospace Surges 72%
Raymond Limited released its earnings call transcript for Q2 and H1 FY27, highlighting total income growth of 21% YoY to ₹683 crore in Q2 FY27, with EBITDA reaching ₹103 crore (15.1% margin). The Aerospace vertical under JK Maini Global Aerospace led growth, rising 72% YoY to ₹139 crore with an EBITDA margin of 21%. The Precision Technology and Auto Component segment posted revenue of ₹471 crore (up 15% YoY) with a 13% EBITDA margin. Management reiterated that its greenfield capacity in Andhra Pradesh remains on schedule for commissioning by Q3 FY28.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the full Q2 and H1 FY27 earnings call transcript with operational details on aerospace and precision engineering segments.
ஏன் இது முக்கியம்Demonstrates successful pivoting into high-margin precision engineering and aerospace platforms, helping diversify revenue away from legacy operations.
Q2 FY27 Total Income: ₹683 கோடிQ2 FY27 Total Income growth: 21% YoYQ2 FY27 EBITDA margin: 15.1%Q2 FY27 Aerospace Revenue: ₹139 கோடிAndhra Pradesh Greenfield Commissioning: Q3 FY28
📅 குறுகிய காலம்Earnings transcript provides positive clarity on order execution and multi-year production schedules, which supports near-term operating sentiment.
📈 நீண்ட காலம்Long lifecycle aerospace program visibility (10-15+ years) and expansion into adjacencies like medical components and gas turbines provide structural growth drivers.
⚠ அபாய எச்சரிக்கைகள்
Raw material and tooling cost inflation alongside elevated freight volatility
Global aerospace OEM supply chain bottlenecks impacting dispatch schedules
👀 கவனிக்க வேண்டியவை
Track capacity ramp-up from brownfield debottlenecking in upcoming quarters and progress on the Andhra Pradesh greenfield project targeted for Q3 FY28.
IMFA Declares ₹5 Interim Dividend; Q2 FY27 Net Profit Up 50.6% YoY to ₹148.77 Cr
Indian Metals & Ferro Alloys Ltd (IMFA) declared an interim dividend of ₹5 per share (50% on ₹10 face value) with a record date of November 12, 2026, payable by December 3, 2026. Concurrently, the company reported Q2 FY27 standalone revenue of ₹968.17 Cr, rising 34.7% YoY, and a net profit of ₹148.77 Cr, up 50.6% YoY. For H1 FY27, net profit grew 78.9% YoY to ₹340.26 Cr on the back of higher ferro chrome volumes and realization. Additionally, the board approved an equity infusion of ₹25 Cr into its wholly owned subsidiary, Metallix Aviation Private Limited.
உச்சம் நம்பிக்கை
என்ன மாறியதுIMFA declared an interim dividend of ₹5 per share and approved a ₹25 Cr equity injection into its subsidiary Metallix Aviation, alongside releasing strong Q2/H1 FY27 financial results.
ஏன் இது முக்கியம்The ₹5 per share payout reflects healthy cash generation supported by a 50.6% YoY surge in Q2 PAT, while ongoing capacity ramps at Kalinganagar continue driving operational volumes.
Interim Dividend: ஒரு ஈக்விட்டி பங்குக்கு ₹5ரெக்கார்ட் தேதி: 12th நவம்பர் 2026Q2 FY27 Revenue: ₹968.17 கோடிQ2 FY27 PAT: ₹148.77 கோடிH1 FY27 PAT: ₹340.26 கோடிSubsidiary Investment: ₹25 கோடி
📅 குறுகிய காலம்The stock will react to the twin catalysts of a strong operational Q2 performance and the ₹5 interim dividend ahead of the November 12 record date.
📈 நீண்ட காலம்Capacity expansion trajectory (moving from 284k TPA towards 534k TPA) combined with integrated cost structures underpins long-term volume growth, though commodity price cycles remain a factor.
⚠ அபாய எச்சரிக்கைகள்
Power and fuel costs increased due to Kalinganagar plant start-up and stabilization
Forex volatility impact on exports and borrowings due to INR depreciation against USD
👀 கவனிக்க வேண்டியவை
Track the ex-dividend date around November 12, 2026, and monitor plant stabilization progress at Kalinganagar along with ferro chrome export realisations over upcoming quarters.
Chemplast Sanmar Q2 Standalone Net Loss Narrows to ₹11.48 Cr; Revenue Up 11.5% YoY to ₹622.14 Cr
Chemplast Sanmar reported standalone revenue from operations of ₹622.14 Cr for Q2 FY27 (ended September 30, 2026), up 11.5% YoY from ₹558.12 Cr. Standalone net loss narrowed significantly to ₹11.48 Cr compared to a net loss of ₹35.53 Cr in Q2 FY26 and ₹49.29 Cr in Q1 FY27. For H1 FY27, standalone revenue reached ₹1,214.46 Cr with a net loss of ₹60.77 Cr. The company also reported a minor fire incident at its Karaikal plant, which resumed operations on September 25, 2026, with insurance recovery assessment underway.
உச்சம் நம்பிக்கை
என்ன மாறியதுChemplast Sanmar reported its Q2 and H1 FY27 financial results, reflecting a sequential and YoY reduction in standalone net losses.
ஏன் இது முக்கியம்While top-line growth saw a modest recovery, the business remains in a net loss position, reflecting ongoing industry pricing headwinds from low-cost imports.
Standalone Revenue (Q2): 622.14 கோடிStandalone Net Loss (Q2): (11.48) CrStandalone Revenue (H1): 1,214.46 கோடிStandalone Net Loss (H1): (60.77) Cr
📅 குறுகிய காலம்Loss reduction may offer moderate sentiment relief, but the pending insurance claim outcome and persistent margin pressure will keep stock movements range-bound.
📈 நீண்ட காலம்Turnaround depends on structural recovery in domestic PVC spreads, trade actions against cheap imports, and commercialization of new specialty blocks (MPB 3 and 4).
⚠ அபாய எச்சரிக்கைகள்
Persistent operational net losses at standalone level
Unquantified losses pending insurance survey from Karaikal plant fire
Raw material price volatility and exposure to cheap imports
👀 கவனிக்க வேண்டியவை
Track the upcoming insurance claim assessment for the Karaikal plant disruption and monitor PVC price realizations and spreads in the upcoming quarters.
BMETRICS H1 PAT jumps 218% YoY to ₹2.87 Cr; Revenue rises 47% to ₹68.72 Cr
Bombay Metrics Supply Chain reported strong performance for the half year ended September 30, 2026 (H1 FY27), with revenue from operations growing 47% YoY to ₹6,872.39 lakh (₹68.72 Cr). PAT surged 218% YoY to ₹287.35 lakh (₹2.87 Cr) from ₹90.31 lakh in H1 FY26, driven by higher operational efficiencies and product sales. EBITDA margins expanded significantly from 4.88% to 7.19%, while basic EPS improved to ₹2.33 compared to ₹0.73 in the year-ago period. Growth was predominantly led by the Transportation & Automobile segment (+115% YoY) and Other Operating Revenue.
உச்சம் நம்பிக்கை
என்ன மாறியதுBMETRICS announced its audited financial results for the six months ended September 2026, marking a sharp operational turnaround compared to both H1 FY26 and H2 FY26.
ஏன் இது முக்கியம்The performance signals sharp profitability recovery after a weak FY26, with half-year PAT (₹2.87 Cr) exceeding the full-year FY26 PAT of ₹1.65 Cr.
📅 குறுகிய காலம்Likely to be viewed positively by the market given the triple-digit profit surge and sequential doubling of EBITDA.
📈 நீண்ட காலம்Company's expansion into new industrial domains such as electrification and data centers could broaden addressable markets if successfully converted into regular production.
⚠ அபாய எச்சரிக்கைகள்
Exposure to export volatility, especially the US market
A sizeable portion of growth came from other operating revenue (₹11.93 Cr vs ₹0.69 Cr YoY)
👀 கவனிக்க வேண்டியவை
Track whether margin expansion can sustain in H2 FY27 amid ongoing export uncertainty and note the progress in new segment development like EV and data centers.
BHAGCHEM Q2 Revenue Up 21% YoY to ₹169.9 Cr, PAT Flat at ₹5.4 Cr on Higher Finance Costs
Bhagiradha Chemicals released its Q2 & H1 FY27 investor presentation. For Q2 FY27, consolidated revenue from operations grew 21.3% YoY to ₹169.9 Cr, while EBITDA increased 50.9% YoY to ₹22.7 Cr. However, Q2 PAT fell 1.8% YoY to ₹5.4 Cr, weighed down by higher depreciation (₹9.0 Cr vs ₹4.0 Cr) and interest expenses (₹7.6 Cr vs ₹4.1 Cr) following capex ramp-up at Bheema Fine Chemicals. For H1 FY27, revenue reached ₹364.9 Cr (+38% YoY) and PAT nearly doubled to ₹18.7 Cr (+98% YoY).
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company published its detailed Q2 & H1 FY27 investor presentation following quarterly results, detailing operational performance across subsidiaries.
ஏன் இது முக்கியம்While volume growth from the Bheema facility is driving topline expansion, heavy depreciation and debt-service costs are capping quarterly net profit conversion.
Q2 FY27 Revenue: ₹169.9 கோடிQ2 FY27 EBITDA: ₹22.7 கோடிQ2 FY27 PAT: ₹5.4 கோடிH1 FY27 Working Capital Outflow: -₹142.1 கோடிCumulative Bheema Capex (2.5 yrs): ~Rs 514 CrsBheema Capex vs Net Worth: ~69.7%
📅 குறுகிய காலம்Muted net profit growth (-59% QoQ, flat YoY) and severe working capital drag on cash flow may keep near-term sentiment cautious.
📈 நீண்ட காலம்Long-term trajectory depends on sustained capacity ramp-up of the 9,002 MT Bheema facility, new molecule introductions, and operating leverage to offset increased fixed costs.
⚠ அபாய எச்சரிக்கைகள்
Negative operating cash flow of -₹93.4 Cr in H1 FY27 due to sharp inventory and debtor buildup
Elevated leverage with total borrowings rising to ~₹367.8 Cr (D/E up to 0.5x)
Weather disruptions and rainfall deficits impacting domestic agrochemical demand
👀 கவனிக்க வேண்டியவை
Track capacity ramp-up and margin stabilization at the Bheema Fine Chemicals plant, along with working capital normalization as debt-to-equity increased to 0.5x in H1 FY27.
CRISIL Upgrades Sahajanand Medical Technologies Bank Facility Ratings to CRISIL A-/Stable
CRISIL Ratings has upgraded the bank loan facilities of Sahajanand Medical Technologies Limited (SMTL) from 'CRISIL BBB+/Stable/CRISIL A2' to 'CRISIL A-/Stable/CRISIL A2+' across an enhanced amount of Rs 300 crore. Additionally, ratings for its wholly owned subsidiary SMT Cardiovascular Private Limited were upgraded to 'CRISIL BBB+/Stable' for Rs 50 crore of facilities. The upgrade reflects a strengthening business risk profile, with FY26 operating revenue climbing 18% to Rs 1,214 crore alongside stable operating margins of 13.14%. SMTL's capital structure also improved, with gearing decreasing to 0.43 times and net worth increasing to Rs 633 crore as of March 31, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுCRISIL upgraded SMTL's long-term rating by one notch from CRISIL BBB+ to CRISIL A- (and short-term from A2 to A2+), while expanding the rated facility limit to Rs 300 crore.
ஏன் இது முக்கியம்The credit upgrade validates improving scale and financial risk profile, which should help lower debt financing costs and enhance access to institutional credit.
Total rated bank facilities: Rs 300 CroreFY26 Operating Revenue: Rs 1,214 croreFY26 Operating Margin: 13.14%Gearing (as of March 31, 2026): 0.43 timeSubsidiary rated facilities: Rs 50 Crores
📅 குறுகிய காலம்Borrowing terms and interest costs on working capital lines may see marginal softening following the one-notch upgrade.
📈 நீண்ட காலம்Demonstrates structural resilience in the medical devices and stent market with international expansion supporting sustained scale and balance-sheet deleveraging.
⚠ அபாய எச்சரிக்கைகள்
Large working capital requirement with Gross Current Assets high at 220-249 days
Susceptibility to regulatory price caps (e.g., NPPA) and unhedged foreign exchange fluctuations (imports 70-75% of raw materials)
👀 கவனிக்க வேண்டியவை
Watch upcoming quarterly earnings to track whether operating margins sustain above 13% and observe working capital cycle improvements from the elevated ~220-249 days gross current assets level.
Q2 FY27 PAT Jumps 544% YoY to ₹51 Cr; Consolidated AUM Crosses ₹3,000 Cr Milestone
Arman Financial Services reported a 544% YoY increase in consolidated Profit After Tax (PAT) to an all-time high of ₹51 crore for Q2 FY27, up from ₹8 crore in Q2 FY26. Consolidated AUM crossed ₹3,000 crore for the first time, reaching ₹3,209 crore, marking a 51% YoY growth. Consolidated disbursements surged 72% YoY to ₹818 crore, while gross total income grew 48% YoY to ₹235 crore. Asset quality showed resilience with GNPA at 2.73% and NNPA at 0.92%, supported by a strong capital adequacy ratio of 36.26% at Arman and 37.19% at its MFI subsidiary, Namra.
உச்சம் நம்பிக்கை
என்ன மாறியதுArman posted record quarterly profitability (PAT of ₹51 crore) and crossed the ₹3,000 crore AUM mark driven by strong disbursements across both microfinance and standalone books.
ஏன் இது முக்கியம்Demonstrates sustained recovery in profitability and asset quality over four consecutive quarters following credit underwriting and collection structural overhauls.
📅 குறுகிய காலம்Strong operational turnaround and surging earnings should drive positive market sentiment over the near term.
📈 நீண்ட காலம்The strategic pivot to individual lending, diversified secured books (MSME/LAP), and branch separation of credit/collections underpins structural scalability, provided rural credit risks remain contained.
⚠ அபாய எச்சரிக்கைகள்
Drought declarations in Maharashtra and Karnataka affecting 7.60% of consolidated AUM
Pending regulatory approval for the renewal of the CGFMU credit guarantee scheme
👀 கவனிக்க வேண்டியவை
Track the impact of drought declarations in Maharashtra and Karnataka (representing 7.60% of AUM) on asset quality, along with the regulatory renewal status of the CGFMU scheme.
Trom Industries Wins ₹3.21 Cr Solar Rooftop Order from Zydus Pharmaceuticals
Trom Industries Limited has secured a purchase order valued at ₹3,20,99,996 from M/s. Zydus Pharmaceuticals Limited. The contract entails the supply, design, installation, testing, and commissioning of a 1MW solar rooftop power plant. The project is categorized as an international order (SEZ) and is scheduled for completion within 12 months. This contract represents approximately 1.5% of the company's TTM revenue of ₹216 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுTrom Industries secured a new commercial contract worth ₹3.21 Cr for a 1MW solar rooftop setup from Zydus Pharmaceuticals.
ஏன் இது முக்கியம்While modest at ~1.5% of TTM revenue, the order demonstrates continued client addition in the industrial and pharma SEZ segments.
Order value: INR 3,20,99,996.00/-Capacity: 1MWசெயல்படுத்தும் காலம்: within 12 monthsOrder vs TTM revenue: ~1.5%
📅 குறுகிய காலம்Marginally positive sentiment from contract momentum, though the order size is relatively small relative to annual revenue.
📈 நீண்ட காலம்Limited; routine addition to order book that reinforces execution capabilities in corporate rooftop solar.
⚠ அபாய எச்சரிக்கைகள்
Execution timeline risk over 12 months
Potential raw material input price fluctuations
👀 கவனிக்க வேண்டியவை
Track execution milestones and revenue recognition over the 12-month period in upcoming quarterly disclosures.
Manaksia Coated Q2 FY27 Call: Rs 525 Cr Order Book, 1.5 Lakh MT Line & Rs 150 Cr QIP Planned
Manaksia Coated Metals released its Q2 FY27 earnings call transcript, reporting total income of Rs 321.55 crore (up 43.8% YoY) and PAT of Rs 18.73 crore (up 32.9% QoQ). The company's order book stands at Rs 525 crore (58.5% of TTM revenue of Rs 897 crore), with exports accounting for Rs 420 crore. Management confirmed plans to commission its Second Colour Coating Line (adding 1,50,000 MT/year, a 174% capacity jump) in Q3 FY27. Additionally, the company disclosed it has floated plans for an up to Rs 150 crore QIP primarily targeted at debt reduction.
உச்சம் நம்பிக்கை
என்ன மாறியதுFiling of the detailed transcript of the Q2 and H1 FY27 earnings conference call held on November 2, 2026.
ஏன் இது முக்கியம்Provides visibility on upcoming 174% capacity expansion in value-added pre-painted steel, healthy export order book, and potential balance sheet deleveraging via equity raise.
Total Order Book: ரூ. 525 கோடிOrder book vs TTM revenue: ~58.5%Proposed QIP raise: up to Rs. 150 croresQIP vs Market Cap: ~10.2%Capacity expansion: 1,50,000 metric tons per annumQ2 FY27 Total Income: ரூ. 321.55 கோடி
📅 குறுகிய காலம்Positive operational sentiment driven by Q2 profit growth and strong visibility from the Rs 525 crore order book scheduled over the next 5 months.
📈 நீண்ட காலம்Structural transformation towards value-added pre-painted steel and Alu-zinc exports, supported by a 174% capacity increase and captive solar power cost savings.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution from planned Rs 150 crore QIP
Global raw material price and freight volatility affecting export margins
👀 கவனிக்க வேண்டியவை
Track the commercial commissioning of the 1,50,000 MTPA colour coating line and 7 MW solar plant in Q3 FY27, alongside dilution terms and progress on the proposed Rs 150 crore QIP.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
